trending Market Intelligence /marketintelligence/en/news-insights/trending/acowhar7xtzketmvmwt5ga2 content esgSubNav
In This List

Therapure Biopharma's biologics unit plans IPO

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Therapure Biopharma's biologics unit plans IPO

Therapure Biopharma Inc..'s biologics division, Evolve Biologics, confidentially submitted a draft registration statement for an IPO in the U.S.

The IPO is expected to commence after the U.S. Securities and Exchange Commission completes its review process, subject to market and other conditions.

The Mississauga, Canada-based privately held company's biologics unit separates proteins from blood's plasma for use in treating diseases.